Messenger RNA (mRNA) News and Research

RSS

Study finds miRNAs inhibits prostate cancer metastasis

A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. A research team led by scientists at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine.

18 Jan 2011

Genetic information from Guthrie cards may serve as valuable resource to diagnose infant diseases

Van Andel Research Institute researchers have developed a method that can yield more information from archived newborn blood that has implications for a vast array of research, including population health studies and answering questions about diseases in infants and children.

13 Jan 2011

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Beth Israel Deaconess Medical Center cancer geneticist Pier Paolo Pandolfi, MD, PhD, is the recipient of the 2011 Pezcoller Foundation-AACR (American Association of Cancer Research) International Award for Cancer Research.

13 Jan 2011

Study highlights important clinical implications of miR-503 in diabetes-associated vascular complications

New research has found one of the smallest entities in the human genome, micro-RNA, could increase the risk of limb amputation in diabetic patients who have poor blood flow.

13 Jan 2011

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).

10 Jan 2011

Research suggests novel therapeutic approach for Huntington's Disease

Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.

10 Jan 2011

New mechanisms of resistance to chemotherapy among leukemia patients

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.

10 Jan 2011

Mutated TDP-43 can cause neurons to die: Study

Lou Gehrig's disease, or amyotrophic lateral sclerosis, and frontotemporal lobar degeneration are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps.

6 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc., today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

5 Jan 2011

Fungus may provide clue about human response to changes in circadian rhythm

Humans are not the only species ruled by a circadian rhythm. Even simple organisms like moulds are governed by an inner clock. Studying red bread mould may teach us how our own internal clock works. This is exactly what the Centre for Organelle Research at the University of Stavanger, Norway is doing.

30 Dec 2010

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

Scientist discovers molecular switch controlling synthesis of ribosomes

A scientist from the Florida campus of The Scripps Research Institute has discovered a molecular switch that controls the synthesis of ribosomes. Ribosomes are the large machineries inside all living cells that produce proteins, the basic working units of any cell. These new findings offer a novel target for potential treatments for a range of diseases, including cancer.

23 Dec 2010

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Whites with mutations more likely to be susceptible to cocaine abuse

Nearly one in five whites could carry a genetic variant that substantially increases their odds of being susceptible to severe cocaine abuse, according to new research.

21 Dec 2010

Genetic breakthrough in lung cancer

For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.

16 Dec 2010

Messenger RNA (mRNA) News and Research

Study finds miRNAs inhibits prostate cancer metastasis

Genetic information from Guthrie cards may serve as valuable resource to diagnose infant diseases

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Study highlights important clinical implications of miR-503 in diabetes-associated vascular complications

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Research suggests novel therapeutic approach for Huntington's Disease

New mechanisms of resistance to chemotherapy among leukemia patients

Mutated TDP-43 can cause neurons to die: Study

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Fungus may provide clue about human response to changes in circadian rhythm

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Scientist discovers molecular switch controlling synthesis of ribosomes

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Whites with mutations more likely to be susceptible to cocaine abuse

Genetic breakthrough in lung cancer

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

eBook: A guide to RNA sequencing eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News